Abstract:
The present invention relates to the compounds of formula (I),
wherein: R¹ is hydrogen, hydroxy or amino; R² is hydrogen, hydroxy, methoxy or methoxymethoxy; R³ is hydrogen, hydroxy, amino, methoxy, methoxymethoxy or, taken together with R², methylenedioxy (also known as 1,3 dioxolo); R⁴ is hydrogen, hydroxy, methoxy, methoxymethoxy, benzyl, di(C₁₋₄)alkylaminomethyl or, taken together with R³, methylenedioxy; R⁵ is hydrogen or hydroxy; provided that at least one of R¹ through R⁵ is other than hydrogen; and
i) X² is hydroxy or methoxy with X¹, X³ and X⁴ being hydrogen; or ii) X¹ taken together with X², X² taken together with X³ or X³ taken together with X⁴, is methylenedioxy, provided that each of the remaining respective X¹, X², X³ and X⁴ substituents are hydrogen, intermediates in the synthesis of them, pharmaceutical formulation containing them, their use as inhibitors of topoisomerase and their use in the treatment of tumors.
Abstract translation:本发明涉及式(I)化合物,其中:R 1是氢,羟基或氨基; R 2是氢,羟基,甲氧基或甲氧基甲氧基; R 3为氢,羟基,氨基,甲氧基,甲氧基甲氧基,或与R 2一起亚甲二氧基(也称为1,3-二氧杂环戊烷)一起使用。 R 4是氢,羟基,甲氧基,甲氧基甲氧基,苄基,二(C1-4)烷基氨基甲基或与R 3一起亚甲二氧基; R 5是氢或羟基; 条件是R 1至R 5中的至少一个不是氢; 和i)X 2是羟基或甲氧基,X 1,X 3和X 4是氢; 或ii)与X 2一起X,X 2与X 3或X 3一起与X 4一起使用的X 1是亚甲二氧基,条件是剩余的各自的X X 1,X 3和X 4取代基是氢,它们的合成中的中间体,含有它们的药物制剂,它们作为拓扑异构酶的抑制剂的用途及其在治疗肿瘤中的用途。